This press-release (German version) is protected by “doc-check”
Friday - October 29, 2021
Not intended for U.S. and UK Media

European Patent Office maintained Bayer patent on the once-daily administration of rivaroxaban (Xarelto™)

Berlin, October 29, 2021 – The European Patent Office has reversed a first instance decision and maintained a Bayer patent (EP 1 845 961) on the once-daily administration of rivaroxaban (Xarelto™; 10, 15 and 20 mg). The 2.5 mg dose is not affected.

Several generic drug manufacturers had initially successfully opposed the patent. With this decision of the European Patent Office, this patent is still valid until mid-January 2026, therefore almost two years longer than the extended compound patent protection until early April 2024. Until then, it will not be possible in EU countries (except Malta) and certain non-EU countries (e.g. UK, Switzerland) to launch generic rivaroxaban that is intended to be administered once a day without infringing the patent. At country level the option to challenge the patent remains. Bayer welcomes the positive decision strengthening the patent and will continue to vigorously defend its intellectual property.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to

Find more information at
Follow us on Facebook:
Follow us on Twitter: @BayerPharma

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Download Center
file(s) collected

View Download Center


Richard Breum

Phone +49 30 468-17112
Phone +49 214 30-72704